Leuprolide acetate 3.75mg; depot susp for IM inj; preservative-free. Leuprolide acetate is a long-acting GnRH analog. A single monthly injection of results in an initial stimulation followed by a ...

ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...

Madison, Wis., January 20, 2015 -- Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug ...

ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cvwck3/lupron_depot) has announced the addition of GlobalData's new report ...

Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...

AbbVie announced that a new 6-month 45mg Lupron Depot (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced ...